Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L19IL2 + gemcitabine
- Development stage
- Unknown
- Lead developer
- Philogen
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
L19IL2 + gemcitabine is a combination therapy under investigation for advanced solid tumors, particularly pancreatic cancer. L19IL2 is a recombinant fusion protein consisting of interleukin-2 (IL-2) fused to the single-chain monoclonal antibody fragment L19, which targets the extradomain B of fibronectin—a marker of tumor angiogenesis. This design allows targeted delivery of IL-2 to the tumor microenvironment, enhancing local immune activation while reducing systemic toxicity[8]. Gemcitabine is a nucleoside analog and antimetabolite chemotherapy agent that inhibits DNA synthesis by blocking ribonucleotide reductase and incorporating into DNA strands during replication[4]. The rationale for combining these agents is that gemcitabine’s cytotoxic effects may synergize with the immunostimulatory activity of targeted IL-2 delivery to improve anti-tumor efficacy. Early-phase clinical trials are ongoing in advanced pancreatic cancer and other solid tumors[5].
- Brand names
- Gemzar
- Other names
- L19-IL2L-19-IL2L 19-IL2recombinant fusion protein IL2-L19gemcitabine hydrochloride
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)RRM2RRM1ED-B (Fibronectin extra domain B)
Beyond the preview
Go deeper on L19IL2 + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L19IL2 + gemcitabine.